Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy

Comment: Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy

Luminal A-type breast cancer patients with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy

Biomarker analysis of the NeoALTTO trial provides oncofertility insight for younger breast cancer patients

ASCO 2022: Highlights and analysis

Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer without prior chemotherapy patients

ASCO 2022: Breast cancer highlights

Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03

Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 expression

Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients